Updates in HER2+ Breast Cancer
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses recent updates in the field of HER2+ breast cancer.
Clinical Pearls:
- There have been advances in HER2+ breast cancer within the past few years
- HER2+ breast caner used to be one of the worst breast cancers to have, but today it is considered to be a “favorable” type of cancer to have
- The risk of recurrence with early-stage HER2+ breast cancer is low, but advanced HER2+ breast cancer cannot be cured because patients ultimately become resistant to therapy
- The HER2 signaling pathway has variations in it from cancer cell to cancer cell that can make the signaling pathway impeded
- Pertuzumab, when combination with trastuzumab, binds to a different part of the HER2 receptor
- This combination, along with chemotherapy, can reduce the amount of recurrences over time
- Although progression-free survival is improved with this combination, patients ultimately become resistant
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
